ICICI Prudential Nifty Pharma Index Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Pharma Total Return IndexCheck Portfolio Overlap →
NAV: ₹20.66+0.74%
07 Sept 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for ICICI Prudential Nifty Pharma Index Fund Direct-Growth.
Market Cap Distribution
Large Cap (47.7%)
Mid Cap (45.6%)
Small Cap (6.7%)
Historical Asset Allocation
| Asset | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 |
|---|---|---|---|---|---|---|
| Equity | 99.96% | 99.94% | 99.50% | 99.94% | 99.86% | 99.35% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 0.04% | 0.06% | 0.50% | 0.06% | 0.14% | 0.65% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
21
P/E Ratio
35.91
P/B Ratio
4.62
Top Holding %
21.33%
Top 5 Holdings %
54.83%
Top 10 Holdings %
79.09%
AUM
₹148 Cr
Expense Ratio
0.51%
Since Inception
21.45%
Max Drawdown
-0.17%
Alpha
-0.41%
Sharpe Ratio
0.96
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 1,58,564 | 31.56 | 21.33% | 0.02%↑ |
| Divis Laboratories Ltd. | Healthcare | 19,027 | 15.33 | 10.36% | 1.32%↑ |
| Cipla Ltd. | Healthcare | 84,259 | 12.41 | 8.39% | -0.52%↓ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 21,962 | 11.25 | 7.60% | 2.36%↑ |
| Laurus Labs Ltd. | Healthcare | 58,261 | 10.58 | 7.15% | 0.77%↑ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 91,282 | 10.48 | 7.08% | -1.86%↓ |
| Lupin Ltd. | Healthcare | 36,364 | 8.78 | 5.94% | -0.41%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 41,447 | 6.55 | 4.43% | -0.30%↓ |
| Alkem Laboratories Ltd. | Healthcare | 8,759 | 5.04 | 3.40% | -0.12%↓ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 22,544 | 5.04 | 3.40% | -0.18%↓ |
| Biocon Ltd. | Healthcare | 1,06,836 | 4.55 | 3.07% | -0.15%↓ |
| Zydus Lifesciences Ltd. | Healthcare | 37,462 | 4.22 | 2.85% | -0.16%↓ |
| Mankind Pharma Ltd. | Healthcare | 16,950 | 4.19 | 2.83% | -0.29%↓ |
| Ipca Laboratories Ltd. | Healthcare | 20,798 | 3.64 | 2.46% | -0.10%↓ |
| Gland Pharma Ltd. | Healthcare | 11,927 | 2.99 | 2.02% | -0.13%↓ |
| Sai Life Sciences Ltd. | Healthcare | 20,658 | 2.72 | 1.84% | - |
| Wockhardt Ltd. | Healthcare | 12,362 | 2.42 | 1.64% | -0.10%↓ |
| Ajanta Pharma Ltd. | Healthcare | 6,302 | 2.18 | 1.48% | -0.08%↓ |
| Abbott India Ltd. | Healthcare | 777 | 2.16 | 1.46% | 0.03%↑ |
| Piramal Pharma Ltd. | Healthcare | 93,138 | 1.82 | 1.23% | 0.10%↑ |
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 99.96% | 99.94% | 99.50% | 99.94% | 99.86% | 99.35% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
34.7 / 100
Weighted average Value score is 34.7. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
71.8 / 100
Weighted average Price Momentum score is 71.8. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
84.8 / 100
Weighted average Quality score is 84.8. This indicates that portfolio has high quality using composite of quality measures.
QVM score
76.7 / 100
Weighted average QVM score is 76.7. This indicates that portfolio has high QVM score and hence could be considered for investment.
Red Flags
Frequently Asked Questions
What are the top holdings of ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
The top holdings of ICICI Prudential Nifty Pharma Index Fund Direct-Growth as of 31 Jul 2026 are Sun Pharmaceutical Industries Ltd. (21.33%), Divis Laboratories Ltd. (10.36%), Cipla Ltd. (8.39%), Torrent Pharmaceuticals Ltd. (7.60%), Laurus Labs Ltd. (7.15%). These top 5 stocks together account for 54.83% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does ICICI Prudential Nifty Pharma Index Fund Direct-Growth hold in its portfolio?
ICICI Prudential Nifty Pharma Index Fund Direct-Growth holds 21 stocks in its portfolio as of 31 Jul 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
As of 31 Jul 2026, ICICI Prudential Nifty Pharma Index Fund Direct-Growth's top sector allocations are Healthcare (99.96%). You can find detailed sector allocation above.
What is the equity and debt allocation of ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
As of 31 Jul 2026, ICICI Prudential Nifty Pharma Index Fund Direct-Growth has 99.96% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
As of 31 Jul 2026, ICICI Prudential Nifty Pharma Index Fund Direct-Growth's market cap allocation is 47.70% in large caps, 45.57% in mid caps, and 6.73% in small caps.
What is the PE ratio of ICICI Prudential Nifty Pharma Index Fund Direct-Growth's portfolio?
The portfolio PE ratio of ICICI Prudential Nifty Pharma Index Fund Direct-Growth is 35.91 as of 31 Jul 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
A credit rating breakdown is not available for ICICI Prudential Nifty Pharma Index Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for ICICI Prudential Nifty Pharma Index Fund Direct-Growth?
The latest portfolio disclosure for ICICI Prudential Nifty Pharma Index Fund Direct-Growth is as of 31 Jul 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.